Ledesma, D., Berriatua, E., Thomas, MC., Benal, LJ., Papasouliotis, K., Ortuno, M., ... Lopez, MC. (2017). Performance of Leishmania PFR1 recombinant antigen in serological diagnosis of asymptomatic canine leishmaniosis by ELISA. *BMC Veterinary Research, 13*, [304]. https://doi.org/10.1186/s12917-017-1224-z

Publisher's PDF, also known as Version of record

License (if available):
CC BY

Link to published version (if available):
10.1186/s12917-017-1224-z

[Link to publication record in Explore Bristol Research](https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-017-1224-z)

PDF-document

---

This is the final published version of the article (version of record). It first appeared online via BioMed Central at https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-017-1224-z . Please refer to any applicable terms of use of the publisher.

---

**University of Bristol - Explore Bristol Research**

**General rights**

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms
Performance of *Leishmania* PFR1 recombinant antigen in serological diagnosis of asymptomatic canine leishmaniosis by ELISA

Darién Ledesma, Eduardo Berriatua, M. Carmen Thomas, Luis Jesús Bernal, María Ortuño, Celia Benitez, Adriana Egui, Kostas Papasouliotis, Bryn Tennant, Julia Chambers, Juan José Infante and Manuel Carlos López

**Abstract**

**Background:** *Leishmania infantum* is a protozoan parasite transmitted by phlebotomine sand flies that causes life-threatening disease in humans and dogs. The dog is the primary reservoir of the parasite and early diagnosis of canine leishmaniosis is crucial at the clinical and epidemiological level. The currently available serological tests for CanL diagnostic show limitations therefore the aim of the present study was to investigate the diagnostic performance of an indirect antibody ELISA based on the *Leishmania infantum* recombinant antigen PFR1 in asymptotically infected dogs. One hundred fifty-six dogs including *Leishmania*-free experimental Beagles and pet dogs from England, Scotland and Leishmania-endemic Murcia in Spain, were tested with the assay. The later were also tested with two commercial *L. infantum* crude antigen ELISAs (INgezim and Civtest, respectively) and a real-time kinetoplast PCR test.

**Results:** Anti-PFR1 antibodies were detected in the four groups of dogs, and the mean log-transformed optical density (OD) values were lowest in Beagles and in dogs from England and highest among dogs from Murcia (p < 0.05). Using the highest OD in beagles as the PFR1 ELISA cut-off point, the estimated seroprevalence was 27% (14-40%) in dogs from Murcia, 4% (0-9%) in dogs from Scotland and 3% (0-8%) in dogs from England (p < 0.05). Seroprevalence in dogs from Murcia according to the INgezim and Civtest ELISAs were 24% (12-37%) and 31% (18-45%), respectively, whilst the prevalence of infection based on PCR in these dogs was 73% (60-86). The percentages of PFR1-positive dogs that tested negative on the INgezim and Civtest ELISAs were 30% and 35%, respectively, and all of them tested positive on the PCR test. Relative to the PCR, the specificity, sensitivity and area under the ROC curve of the PFR1 ELISA were 100%, 36% and 0.74 (0.63-0.86), respectively.

**Conclusions:** The ability shown by the PFR1 ELISA to detect infected dogs that go undetected by the crude antigen ELISAs is clinically and epidemiologically useful and PFR1 could be considered a candidate for a multi-antigen-based immunoassay for early detection of *L. infantum* infected dogs.

**Keywords:** Canine, Leishmania, PFR1 recombinant antigen, Serological, Diagnosis

* Correspondence: berriatu@um.es; mclopez@ipb.csic.es
1Departamento de Sanidad Animal, Universidad de Murcia, Murcia, Spain
2Instituto de Parasitología y Biomedicina "López Neyra" Consejo Superior de Investigaciones Científicas, Granada, Spain
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

*Leishmania infantum* (*L. infantum*) transmitted by phlebotomine sand flies, infects reticuloendothelial cells causing potentially life-threatening human and canine leishmaniosis (CanL). Since the advent of PCR diagnosis, it has been found that 50-80% of dogs endemic to areas such as the Murcia Region in Southeast Spain are chronically infected and that most remain asymptomatic [1]. The development of the disease is strongly influenced by the host’s immunity, which tends to be polarized towards either a Th1 cell- or a Th2 antibody-mediated response [2, 3]. The latter is commonly associated with disease susceptibility resulting from the widespread deposition of antibody-antigen complexes in capillaries. Subclinically infected dogs, particularly those in preclinical stages, may transmit infection to sand flies [4, 5]. Consequently, serological diagnosis of *Leishmania* infection is clinically and epidemiologically useful.

The estimated seroprevalence of CanL in endemic areas is typically 10-30% depending on the dog’s habitat and exposure to infection as well as on the sensitivity (Se) and specificity (Sp) of the diagnostic test. Se and Sp vary according to the antigens used - crude, soluble, purified or recombinant antigens - and the immunological method used for detection. The most common types of immunoassay used for epidemiological and surveillance purposes are indirect immunofluorescence assays (IFAs), enzyme-linked immunosorbent assays (ELISAs), and rapid immunochromatographic tests (ICTs) [6, 7]. The IFA is considered the reference test. However, its Se may range from 60% to 100% [8, 9], and it is known that false positives may arise from cross-reactivity with other protozoan and bacterial infections [7, 10, 11]. The antigens used in these types of tests might be either crude antigens obtained from cultures of the parasite or recombinant antigens expressed in heterologous expression systems. The tests based on recombinant antigens are more specific and easier to produce and standardize and have been used for *Leishmania* spp. serodiagnosis in human and dogs [12–15]. Among the antigens composing these tests, rK39, a repetitive, conserved, protein in *Leishmania donovani* complex species [16], has been widely used. The validity of tests based on rK39 depends on time since infection and presence of active disease. In a recent meta-analysis study, the overall Se of rK39-based ICT tests in infected asymptomatic dogs was only 50% [17]. The authors suggested that using a combination of recombinant antigens should improve test Se. The advantage of this approach in the serological diagnosis of *L. infantum* infection in dogs was later shown [14].

In the search for vaccine candidates, a highly immunogenic protein from *L. infantum* named PFR1 was cloned and expressed as recombinant protein. PFRs, or paraflagellar rod proteins, represent a family of relevant trypanosomatid antigens located in the paraflagellar pocket of these parasites [18–20]. Knock-out assays in *Leishmania mexicana* evidenced that the proteins encoded by PFR genes play a critical role in the mobility and survival of the parasite [21]. Some members of the PFR antigen family stand out for their high immunogenicity [22]. The sera from both asymptomatic and cardiac Chagas’ disease patients showed a higher level of antibodies against PFR antigens of *Trypanosoma cruzi* (*T. cruzi*) than sera from healthy donors [23].

Given the limitations of presently available serological tests for CanL and the high immunogenicity of PFR antigens, the present article evaluated the seroreactivity of dogs to the PFR1 recombinant protein and the validity of a PFR1-based ELISA for the diagnosis of asymptomatic CanL.

Methods

Cloning of PFR1 coding sequence in pQE32 expression vector; overexpression and purification of the PFR1 recombinant antigen

The PFR1 coding sequence was amplified by PCR using *L. infantum* genomic DNA as a template along with the primers PFR1Li-ATG (5’GAATGGATCCCCCTGAAGAGTA) and PFR1Li-TAAKpn1 (5’GTAAGGTAACCCCTCCAGCTGCGTGCCTCG3’), which bear BamHI and KpnI restriction sites, respectively. The 1775 bp amplified fragment was cloned into a pQE-32 vector. The recombinant PFR1 protein was overexpressed by adding 0.02 mM of isopropyl-beta-D-thiogalactopyranoside (IPTG) to the *E. coli* M15 strain transformed with pQE-32-PFR1Li and grown for 3 h at 37 °C. Total proteins were solubilized in solubilization buffer (0.3 M NaCl, 50 mM NaH2PO4, 1 mM phenyl methyl sulfonyl fluoride, pH 8.0) and by sonication. Recombinant PFR1 was subsequently purified to homogeneity under native conditions by Ni2+-NTA affinity chromatography to a 6× histidine tag placed at the NH2-terminus of PFR1. After washing, the protein was eluted in solubilization buffer at pH 6.0. The final elution fraction resulting from the purification process was analysed in triplicate by 10% SDS-PAGE and Coomassie Blue staining (Fig. 1). The protein concentration was measured with a Micro BCA Protein Assay Kit (Thermo).

The recombinant PFR1 protein was overexpressed by adding 0.02 mM of isopropyl-beta-D-thiogalactopyranoside (IPTG) to the *E. coli* M15 strain transformed with pQE-32-PFR1Li and grown for 3 h at 37 °C. Total proteins were solubilized in solubilization buffer (0.3 M NaCl, 50 mM NaH2PO4, 1 mM phenyl methyl sulfonyl fluoride, pH 8.0) and by sonication. Recombinant PFR1 was subsequently purified to homogeneity under native conditions by Ni2+-NTA affinity chromatography to a 6× histidine tag placed at the NH2-terminus of PFR1. After washing, the protein was eluted in solubilization buffer at pH 6.0. The final elution fraction resulting from the purification process was analysed in triplicate by 10% SDS-PAGE and Coomassie Blue staining (Fig. 1). The protein concentration was measured with a Micro BCA Protein Assay Kit (Thermo).
Western blot analysis

Purified PFR1 recombinant protein was electrophoresed in a 10% SDS-PAGE and transferred to PVDF membranes (Immobilon-P) by following standard procedures as previously described [24]. Western blotting was performed in duplicate according to standard techniques. For PFR1 detection, an antibody raised against the PFR2 protein of \textit{T. cruzi} was used as primary antibody [20] at 1:2000 dilution. The secondary antibody was an HRP-conjugated anti-rabbit IgG (Sigma) at 1:20,000 dilution. The blots were subjected to peroxidase and luminol/enhancer solutions using a SuperSignal® West Pico Chemiluminescent Reagent Kit (Thermo Scientific), and subsequently exposed to Kodak X-Omat autoradiographic film.

Detection of specific anti-PFR1 antibodies by ELISA

Serum from all dogs, obtained from blood samples collected from the cephalic vein into vacuum tubes, was tested for anti-PFR1 antibodies by ELISA. ELISAs were performed in triplicate at different dilutions by following previously described procedures [26]. Positive and negative control sera were included in all plates. Briefly, ELISA 8-well strips (Nunc-Immuno module F16; Roskilde, Denmark) were coated with 0.5 µg/well of PFR1 in a carbonate buffer. After being coated, the plates were stored in a dry atmosphere at −20 °C until use. The wells were washed twice with 200 µL of PBS-0.05% TWEEN 20 and blocked by incubation for 90 min with 5% non-fat dried milk powder in PBS (blocking solution) at 37 °C. Subsequently, canine sera at 1/100 and 1/200 dilutions in blocking solution were added to the dry blocked wells and incubated for 2 h at 37 °C. Before the secondary antibody
was added, the plates were washed five times with 200 μL of PBS-0.05% TWEEN 20 and incubated for 1 h with peroxidase-conjugated anti-dog IgG (Sigma) in blocking solution at a 1/10000 dilution at 37 °C. After incubation, the plates were washed five times with 200 μL of PBS-0.05% TWEEN 20, and the reaction was developed using ortho-phenylenediamine and hydrogen peroxide in a citrate buffer for 5 min in the dark at room temperature. Finally, 8 N sulfuric acid was used to stop the reaction, and the absorbance was measured at 492 nm.

**Commercial L. infantum antibody ELISAs**

Commercial antibody tests to detect serum *L. infantum* IgG included INgezim Leishmania® (Ingenasa, Spain) and Civtest Canis Leishmania® (Hipra, Spain, later commercialized by Esteve, Spain as Leiscan®). Both tests use crude immunodominant *L. infantum* antigens for capturing specific IgGs. For detection, the INgezim test uses conjugation to a specific canine IgG monoclonal antibody, whilst Civtest uses a generic protein A/HRPO conjugate. The validity of these tests has been assessed by the manufacturers using IFA as the reference test. The INgezim results showed 95% and 80% agreement for 1/100 and 1/160 IFA cut-offs, respectively, whilst the estimated sensitivity (Se) and specificity (Sp) of the Civtest assay were 98% and 96%, respectively. Moreover, the performance of both tests was recently assessed on experimentally infected dogs [27], and Sp was 100% for both tests whilst Se was 98% for Civtest and 78% for INgezim.

Samples were done in duplicate, and antibody optical densities (OD) were read in a spectrophotometer. The mean of the two readings was used to classify samples as positive, negative, or inconclusive by following the manufacturers’ instructions.

**L. infantum-specific real-time PCR**

Tissue samples from dogs of the Murcia group were stored at −20 °C until used for DNA purification using a nucleic acid purification robot (Maxwell® 16, Promega). Bone-marrow samples of Beagles were obtained by needle aspiration, mixed with a protein digestion solution (10 mM Tris-HCl, 10 mM NaCl, 10 mM EDTA, pH = 8; 0.1 mg/ml of proteinase K and 1% of SDS) and the DNA was extracted within 48 h with DNeasy Blood and tissue kit, Quiagen.. The DNA was analysed for *L. infantum* kinetoplast sequences using a TaqMan probe in a real-time PCR [28, 29]. The analyses were done in duplicate using 300 ng of high-quality template DNA (A260/A280 ≥ 1.7) per PCR reaction. Samples from dogs with clinical leishmaniosis and uninfected dogs were used as positive and negative amplification controls, respectively. A semi-quantitative measure of parasite DNA load was obtained by estimating the PCR amplification threshold cycle (CT) at which near-logarithmic PCR product generation was detected [30]. Samples with CT = 1-38 were considered positive.

**Statistical analysis**

Analyses were carried out in R (http://www.R-project.org). Anti-PFR1 antibody OD distributions were analysed and normalized using a decimal logarithmic transformation of ODx100 (LOD). The mean LODs between levels of explanatory variables, including dog origin, gender and age (categorized as ≤1 yrs., 2 yrs., 3 yrs. and ≥4 yrs), were compared using ANOVA. A multivariable linear regression model was then used to investigate the independent contributions of explanatory variables to LOD in dogs of the Murcia group [31].

A LOD cut-off value was selected to classify dogs as seronegative or seropositive by adding one decimal to the largest OD among the *Leishmania*-negative Beagle dogs. Differences in the proportion of seropositive dogs across levels of explanatory variables were analysed using the chi-squared test or with Fisher’s exact test when one of the expected values in the contingency table was less than five [32].

A logistic regression model was developed to analyse the multivariable relationship between the serological status of the Murcia dogs and their age and gender.

Receiver operating characteristic (ROC) curves [33] were used to evaluate the performance of the test and calculate Se, Sp with respect to the PCR test in skin and lymphoid tissue samples, considered the reference test [34].

Cohen’s kappa coefficient [32] was employed to evaluate the degree of agreement between the results of qualitative tests by following the scale: 0, no agreement; >0- < 0.2, slight; 0.2- < 0.4, fair; 0.4- < 0.6, moderate; 0.6-< 0.8, substantial; and >0.8, almost perfect.

A 5% (*p* < 0.05) significance level for a two-tailed test was considered in all comparisons.

**Results**

**Purification of Leishmania infantum recombinant PFR1 protein**

Figure 1a shows the analysis by SDS-PAGE of the PFR1 recombinant protein purified as described in Materials and Methods. An intensely stained band with the expected electrophoretic mobility of approximately 70 kDa was observed (Fig. 1a, lane 3). The purity was >95% as assessed by band densitometry analysis after Coomassie blue staining.

The 70 kDa band was the only one detected by the antibody used in the Western blot (Fig. 1b), therefore indicating the integrity of the purified PFR1 protein. In addition, the purified protein was tested with the E-Toxate reaction kit (Sigma), which showed it to be free from bacterial LPS contaminants.
Antibody optical density distribution for PFR1 ELISA

The mean and median (range) LOD values obtained in the PFR1 ELISA were 0.705 and 0.680 (0.014-1.760), respectively, and differed significantly according to the dogs’ origin (Table 1). Median LODs were lower for beagles and dogs from England than for the Murcia dogs (*p* < 0.05). The remaining differences in median LOD between groups were not statistically significant (*p* < 0.05) (Table 1).

Within the Murcia group, LOD was positively associated with age and the median LOD was greater in females than in males (Table 1). The multivariable linear regression model confirmed the independent association of both age and gender with LOD (results not tabulated) (*p* < 0.05).

Estimated seroprevalence based on the PFR1 and commercial ELISAs. Prevalence based on PCR and diagnostic performance of the PFR1 ELISA

Considering a cut-off LOD of 1.080 - a value one thousandth of a unit higher than the highest LOD in the beagles (Table 1) - PFR1 seroprevalence (95% CI) was 27% (14-40) in dogs from Murcia, 4% (0-9) in dogs from Scotland and 3% (0-8) in dogs from England (*p* < 0.05) (Table 2).

The estimated seroprevalence in dogs from Murcia, according to the INgezim and Civtest ELISAs, was 24% (12-37) and 31% (18-45), respectively. The prevalence of asymptomatic infection assessed by PCR in these dogs was 73% (60-86) (Table 2).

In logistic regression models including gender and age, the probability of being seropositive in dogs from Murcia was not significantly associated to either variable.

Relative to the PCR test, which was performed only in the beagles and Murcia dogs, the PFR1 ELISA Sp and Se at a cut-off of 1.080 were 100% and 36%, respectively. The AUC (95% CI) was 0.74 (0.63-0.86).

Diagnostic agreement between tests

The levels of agreement between the different diagnostic tests performed in dogs from Murcia are shown in Table 3. The kappa coefficient from comparing the PFR1

### Table 1 PFR1 normalized optical density according to origin, age and gender

| Variable | Level | N° dogs | Mean | Percentiles |
|----------|-------|---------|------|-------------|
|          |       |         |      | 0% | 10% | 25% | 50% | 75% | 90% | 100% |
| Origin   | Beagles | 25 | 0.651 | 0.067 | 0.241 | 0.335 | 0.490 | 0.673 | 0.899 | 1.079 |
|          | Murcia  | 45 | 0.706 | 0.247 | 0.563 | 0.653 | 0.746 | 1.160 | 1.245 | 1.760 |
|          | England | 36 | 0.844 | 0.014 | 0.301 | 0.546 | 0.645 | 0.720 | 1.021 | 1.346 |
|          | Scotland| 50 | 0.532 | 0.091 | 0.322 | 0.443 | 0.734 | 0.957 | 1.057 | 1.509 |
|          | All     | 156 | 0.705 | 0.014 | 0.319 | 0.510 | 0.680 | 0.892 | 1.076 | 1.760 |
| Age (years) | ≤1 | 8 | 0.686 | 0.247 | 0.280 | 0.488 | 0.655 | 0.824 | 1.190 | 1.193 |
|          | 2      | 15 | 0.757 | 0.426 | 0.500 | 0.625 | 0.746 | 0.814 | 1.066 | 1.239 |
|          | 3      | 8  | 0.800 | 0.580 | 0.663 | 0.712 | 0.731 | 0.792 | 1.031 | 1.272 |
|          | 4      | 12 | 1.057 | 0.630 | 0.644 | 0.740 | 1.020 | 1.256 | 1.559 | 1.760 |
| Gender   | Male   | 24 | 0.772 | 0.426 | 0.560 | 0.638 | 0.716 | 0.856 | 1.203 | 1.249 |
|          | Female | 19 | 0.978 | 0.294 | 0.634 | 0.724 | 0.845 | 1.216 | 1.340 | 1.760 |

*aDogs from Murcia only*

### Table 2 Estimated PFR1, INgezim and Civtest ELISA seroprevalence according to dog origin, age and gender

| Variable | Level | N° dogs | PFR1 | INgezim | Civtest | PCR |
|----------|-------|---------|------|---------|---------|------|
| Origen   | Murcia| 45 | 27 (14–40) | 24 (12–37) | 31 (18–45) | 73 (60–86) |
|          | Beagles | 25 | 0 (0–0) | – | – | 0 (0–0) |
|          | Scotland | 50 | 4 (0–9) | – | – | – |
|          | England | 36 | 3 (0–8) | – | – | – |
| Age (years) | ≤1 | 8 | 25 (0–55) | 0 (0–0) | 13 (0–35) | 75 (45–100) |
|          | 2 | 15 | 13 (0–31) | 27 (4–49) | 40 (15–65) | 93 (81–100) |
|          | 3 | 8 | 13 (0–35) | 38 (4–71) | 25 (0–55) | 50 (15–85) |
|          | ≥4 | 12 | 50 (22–78) | 25 (1–50) | 33 (7–60) | 67 (40–93) |
| Gender   | Male | 24 | 17 (2–32) | 21 (5–37) | 25 (8–42) | 71 (53–89) |
|          | Female | 19 | 42 (20–64) | 32 (11–52) | 42 (20–64) | 79 (61–97) |

*aDogs from Murcia only*
ELISA with other serological techniques ranged from 0.23 to 0.36 (fair agreement), while the result of comparing the commercial ELISAs INgezim and Civtest was 0.61 (substantial agreement). Comparing the serological tests with the PCR test, the kappa coefficient ranged from 0.14 (slight agreement) for INgezim to 0.28 (fair agreement) for Civtest (Table 3).

Table 4 shows the percentage of discordant samples tested with two serological tests (T1 and T2) and the percentage of these samples that were PCR positive. The percentage of PFR1 ELISA positives that were negative to the INgezim and Civtest ELISAs were 35% and 30%, respectively, and all these samples were PCR positive. On the other hand, the percentage of samples that tested negative on the PFR1 ELISA and positive on the INgezim and Civtest ELISAs were 29% and 40%, respectively, and whilst all of the latter (Civtest ELISAs) were PCR positive, only 80% of the former (INgezim) were PCR positive (Table 4).

**Discussion**

The results obtained in the present study are consistent with PFR1 stimulating a specific antibody response in dogs asymptomatically infected with *L. infantum*. One-third of all seropositive dogs were only detected with the PFR1 ELISA and not by the commercial ELISAs. Conversely, the PFR1 ELISA failed to detect another third of seropositive dogs according to the commercial ELISAs. Together, these results suggest that the PFR1 antigen might be a useful candidate to incorporate in a multi-antigen ELISA for serological detection of asymptomatically infected dogs.

To further explore this use, cross-reactivity between PFR1 and other recombinant antigens used for *Leishmania* infection diagnosis such as the rK39 antigen should be analysed.

Although the UK is a *Leishmania*-free zone, 3-4% of the UK dogs included in this study tested positive to the PFR1 ELISA. This result might indicate that some PFR1 conformational epitopes are shared with proteins present in other pathogens or that the seropositive UK dogs were actually infected with *L. infantum*. The latter cannot be ruled out since the travel history of the UK dogs was unknown and no samples were available for PCR testing. Serological cross-reaction has been reported between *Leishmania* antigens and antigens of other pathogens present in the UK such as *Ehrlichia canis*, *Babesia canis*, *Anaplasma phagocytophilum*, *Rickettsia conori*, *Toxoplasma gondii*, *Neospora caninum* and *Hepatozoon canis* [7, 10, 11, 35]. However, arguing against cross-reactivity, at the selected cut-off LOD of 1.080, the specificity of the PFR1 ELISA relative to the PCR test performed only in beagles and dogs from Murcia was 100%. In comparison, the homologous PFR2 protein from *T. cruzi* is recognized by the sera from asymptomatic chagasic patients with a specificity and sensitivity of 92% and 75%, respectively. It is worth mentioning that the sera from patients with leishmaniasis also recognize this protein.

The sensitivity of the PFR1 ELISA compared to the PCR test was 36%, similar to that estimated for commercial ELISAs. This low sensitivity value might be expected when analysing asymptomatically infected dogs since most dogs develop a predominantly cellular immune response.

**Table 3** Kappa coefficient and degree of agreement between PFR1, INgezim (Ing) and Civtest (Civ) ELISA tests

| Techniques | N° dogs | PFR1 | Ing | Civ | Ing + Civ | PCR |
|------------|---------|------|-----|-----|----------|-----|
| PFR1       | 45      | –    | Fair| Fair| Fair     | Fair|
| Ing        | 45      | 0.36 (0.05–0.67) | –   | Substantial| Substantial| Slight|
| Civ        | 45      | 0.24 (0.00–0.55) | 0.61 (0.36–0.87) | –  | Almost perfect| Fair|
| Ing + Civ  | 45      | 0.28 (0.00–0.57) | 0.74 (0.53–0.95) | 0.90 (0.77–1.00) | –  |
| PCR        | 45      | 0.23 (0.08–0.39) | 0.14 (0.00–0.29) | 0.28 (0.11–0.45) | 0.26 (0.06–0.45) | – |

**Table 4** Percentage of positives to one of two ELISA techniques (T1 and T2) including PFR1, INgezim (Ing) and Civtest (Civ) ELISA tests, and their PCR status

| Techniques | T1+; T2- | % Seropositive | % PCR positive | T1-; T2+ | % Seropositive | % PCR positive |
|------------|----------|----------------|----------------|----------|----------------|----------------|
| PFR1       | Ing      | 30             | 100            | 29       | 80             |
| PFR1       | Civ      | 35             | 100            | 40       | 100            |
| PFR1       | Ing + Civ| 24             | 100            | 43       | 100            |
| Ing        | Civ      | 14             | 50             | 31       | 100            |
| Ing        | Ing + Civ| 0              | –              | 31       | 100            |
| Civ        | Ing + Civ| 0              | –              | 13       | 50             |
response to the parasite while the humoral response might be variable and in some cases undetectable by these tests [34]. The reason why the PFR1 ELISA identified specific antibodies that were not detected by the commercial tests based on crude immunodominant antigens is unclear. In crude antigen extract preparations, specific epitopes might not be available for binding specific antibodies.

PFR1 ELISA LODs and seroprevalence were greater in older dogs and LODs in females compared to males. Given the small number of dogs from Murcia, the accuracy of age and gender-specific estimates in this study was limited. There is no previous evidence of gender-specific susceptibility to leishmaniasis, but increasing seroprevalence during the first years of life is typical and is associated with accumulated exposure to infection [36]. Age- and sex-specific differences between studies depend on the degree to which dogs are naturally exposed to Leishmania infection, which is greatest for dogs living outdoors in peri-urban and rural areas and not receiving preventive insecticidal treatments [25].

In summary, the present study highlights the potential of PFR1 recombinant antigen for L. infantum serological diagnoses. Further studies need to be carried out to investigate the test specificity and its performance when combined with other relevant recombinant antigens for diagnostics of CanL.

Conclusions

PFR1 recombinant antigen detects specific antibody responses in L. infantum-infected dogs and could be a useful antigen to incorporate in a multi-antigen immunoassay to detect asymptotically infected dogs.

Additional file

Additional file 1: Study data. (XLSX 140 kb)

References

1. Chitimia L, Munoz-Garcia CI, Sanchez-Velasco D, Lizana V, Del Rio L, Murcia L, Fisa R, Riera C, Gimenez-Font P, Jimenez-Montalban P, et al. Cryptic Leishmaniosis by Leishmania infantum, a feature of canines only? A study of natural infection in wild rabbits, humans and dogs in southeastern Spain. Vet Parasitol. 2011;181(1):12–6.
2. Reis AB, Martins-Filho OA, Teleira-Carvalho A, Giunchetti RC, Cameiro CM, Mayrink W, Tafuri WL, Correa-Oliveira R. Systemic and compartmentalized immune response in canine visceral leishmaniasis. Vet Immunol Immunopathol. 2009;128(1-3):87–95.
3. McCall LL, Zhang WW, Matalshawski G. Determinants for the development of visceral leishmaniasis disease. PLoS Pathog. 2013;9(1):e1003053.
4. Molina R, Amela C, Nieto J, San-Andres M, Gonzalez F, Castillo JA, Lucientes J, Alvar J. Infectivity of dogs naturally infected with Leishmania infantum to colonized Phlebotomus perniciosus. Trans R Soc Trop Med Hyg. 1994;88(4):491–3.
5. Drahota J, Martin-Martín I, Sumova P, Rohousova I, Jimenez M, Molina R, Volf P. Recombinant antigens from Phlebotomus perniciosus saliva as markers of canine exposure to visceral leishmaniasis vector. PLoS Negl Trop Dis. 2014;8(1):e2597.
6. Maia C, Campino L. Methods for diagnosis of canine leishmaniasis and immune response to infection. Vet Parasitol. 2008;158(4):274–87.
7. Laurenti MD, de Santana Leandro MV Jr, Tomokane TY, De Luca HR, Aschar M, Souza CS, Silva RM, Marcondes M, da Matta VL. Comparative evaluation of the DPP(Ri) CIV rapid test for canine serodiagnosis in area of visceral leishmaniasis. Vet Parasitol. 2014;203(3-4):444–50.
8. Almeida MA, Jesus EE, Sousa-Atta ML, Alves LC, Berne ME, Atta AM. Clinical and serological aspects of visceral leishmaniasis in northeast Brazilian dogs naturally infected with Leishmania chagasi. Vet Parasitol. 2005;127(3-4):227–32.
9. da Silva DA, Madeira Mde F, Abrantes TR, Filho CJ, Figueredo FB. Assessment of serological tests for the diagnosis of canine visceral leishmaniasis. Vet J 2013;195(2):252-61.
10. Solano-Gallego L, Villanueva-Sar S, Carbonell M, Trotta M, Furlanello T, Natale A. Serological diagnosis of canine leishmaniasis: comparison of three commercial ELISA tests (Isercan, ID screen and Leishmania 96), a rapid test (speed Leish K) and an in-house IFAT. Parasit Vectors. 2014;7:111.
11. Zanette MF, Lima VM, Laurenti MD, Rossi CN, Vides JP, Vieira RF, Badaro R, Reed SG. Influence of parasite load on serological diagnosis of canine visceral leishmaniasis. J Vet Med B Bacteriol. 2009;56(9):583-8.
12. Badaro R, Benson D, Eulalia MC, Freire M, Cunha S, Netto EM, Pedral-Sampaio D, Madureira C, Burns JM, Houghton RL, et al. rK99: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis. 1996;173(3):758–61.
13. Carvalho FA, Charest H, Tavares CA, Melashvishi G, Valente EP, Rabello A, Gazzinelli RT, Fernandes AP. Diagnosis of American visceral leishmaniasis in humans and dogs using the recombinant Leishmania donovani A2 antigen. Diagn Microbiol Infect Dis. 2002;43(4):289–95.
14. de Oliveira IQ, Silva RA, Sucupira MV, da Silva ED, Reis AB, Grimaldi G, Jr., Fragas DB, Veras PS. Multi-antigen print immunohassay (MAPIA)-based evaluation of novel recombinant Leishmania infantum antigens for the serodiagnosis of canine visceral leishmaniasis. Parasit Vectors 2015;8:45.
15. Fariahmand M, Nahevianian H. Application of recombinant proteins for Serodiagnosis of visceral leishmaniasis in humans and dogs. Iran Biomed J. 2016;20(3):128–34.
16. Bums JM Jr, Sheffler WG, Benson DR, Ghali HW, Badaro R, Reed SG. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc Natl Acad Sci U S A. 1993;90(2):775–9.
17. Quinrell RJ, Caron C, Rethinger R, Garcez LM, Courtenay O. Evaluation of pfK9 rapid diagnostic tests for canine visceral leishmaniasis: longitudinal study and meta-analysis. PLoS Negl Trop Dis. 2013;7(1):e1992.
18. Fouts DL, Stryker GA, Gorski KS, Miller MJ, Nguyen TV, Wrightsman RA, Manning JE. Evidence for four distinct major protein components in the paraf lagellar rod of Trypanosoma cruzi. J Biol Chem. 1998;273(34):21846–55.
19. Clark AK, Kovaltsovych G, Kandlikar S, Lal S, Stryker GA. Cloning and expression analysis of two novel paraf lagellar rod domain genes found in Trypanosoma cruzi. Parasitol Res. 2005;95(9):312–20.
20. Egui A, Thomas MC, Morell M, Maranon C, Carrilero B, Segovia M, Puerta CJ, Pinazo MJ, Rosas F, Gascon J, et al. Trypanosoma cruzi paraf lagellar rod proteins 2 and 3 contain immunodominant CD8(+)/T-cell epitopes that are recognized by cytotoxic T cells from Chagas disease patients. Mol Immunol. 2012;52(3-4):289–98.
21. Santrich C, Moore L, Sherwin T, Bastin P, Brokaw C, Gull K, LeBowitz JH. A motility function for the paraf lagellar rod of Leishmania parasites revealed by PFR-2 gene knockouts. Mol Biochem Parasitol. 1997;90(1):95–109.
22. Michalowski V, Luhrs K, Rocha MO, Fouts D, Gazzinelli RT, Manning JE. Humoral and cellular immune responses to Trypanosoma cruzi-derived paraf lagellar rod proteins in patients with Chagas’ disease. Infect Immun. 2003;71(6):3165–71.
23. Fernandez-Villegas A, Pinazo MJ, Maranon C, Thomas MC, Posada E, Carrilero B, Segovia M, Gascon J, Lopez MC. Short-term follow-up of chagasic patients after benzonidazole treatment using multiple serological markers. BMC Infect Dis. 2011;11:206.
24. Thomas MC, Longobardo MV, Carmelo E, Marañón C, Planelles L, Patarroyo ME, Alonso C, López MC. Mapping of the antigenic determinants of the T. cruzi kinetoplastid membrane protein-11. Identification of a linear epitope specifically recognized by human Chagasic sera. Clin Exp Immunol. 2001;133(3):665–71.
25. Goyena E, Perez-Gutillas P, Chitimia L, Risueno J, Garcia-Martinez JD, Bernal LJ, Bertauta E. A cross-sectional study of the impact of regular use of insecticides in dogs on canine leishmaniasis seroprevalence in southeast Spain. Prev Vet Med. 2016;124:78–84.
26. Thomas MC, Fernandez-Villegas A, Carrilero B, Maranon C, Saura D, Noya O, Segovia M, Alarcon de Noya B, Alonso C, Lopez MC. Characterization of an immunodominant antigenic epitope from Trypanosoma cruzi as a biomarker of chronic Chagas’ disease pathology. Clin Vaccine Immunol. 2012;19(2):167–73.
27. Rodriguez-Cortes A, Ojeda A, Todoli F, Alberola J. Performance of commercially available serological diagnostic tests to detect Leishmania infantum infection on experimentally infected dogs. Vet Parasitol. 2013;191(3-4):363–6.
28. Mary C, Faraut F, Lascombe L, Dumon H. Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity. J Clin Microbiol. 2004;42(11):5249–55.
29. Martin-Esquer G, Fisa R, Riera C, Rocamora V, Fernandez-Casado A, Barranco C, Serra T, Baro T, Pujo RM. Role of Leishmania sp. infestation in nondiagnostic cutaneous granulomatous lesions: report of a series of patients from a western Mediterranean area. Br J Dermatol. 2009;161(2):320–5.
30. Gomes AH, Amelin M, Mencos S, Pereira-Chioccola VL. Leishmania (V) braziliensis: detection by PCR in biopsies from patients with cutaneous leishmaniasis. Exp Parasitol. 2008;119(3):319–24.
31. Kleinbaum DG, Kupper LL, Muller KE, Nizam A. Applied regression analysis and other multivariable methods. 3rd ed. California: Duxbury Press at Brooks/Cole Publishing Company; 1998.
32. Thrusfield M. Veterinary epidemiology. 3rd ed. Oxford: Blackwell Science; 2007.
33. Robin X, Tuckn N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011:12:77.
34. Baneth G, Routinas AF, Solano-Gallego L, Bourdeau P, Ferrer L. Canine leishmaniosis—new concepts and insights on an expanding zoonosis: part one. Trends Parasitol. 2008;24:324–8.
35. Mettler M, Grimm F, Capelli G, Camp H, Deplazes P. Evaluation of enzyme-linked immunosorbent assays, an immunofluorescent-antibody test, and two rapid tests (immunochromatographic-dipstick and gel tests) for serological diagnosis of symptomatic and asymptomatic Leishmania infections in dogs. J Clin Microbiol. 2005;43(11):5513–9.
36. Avar J, Canavate C, Molina R, Moreno J, Nieto J. Canine leishmaniasis. Adv Parasitol. 2004;57:1–88.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit